Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic

INTRODUCTION: In patients with rheumatoid arthritis (RA) who have an inadequate response to or intolerance of their first biologic disease-modifying antirheumatic drug (bDMARD), guidelines recommend switching to a different biologic class. The objective of this study was to compare persistence with...

Descripción completa

Detalles Bibliográficos
Autores principales: Best, Jennie H., Vlad, Steven C., Tominna, Lenore, Abbass, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211223/
https://www.ncbi.nlm.nih.gov/pubmed/32227284
http://dx.doi.org/10.1007/s40744-020-00201-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211223/
https://www.ncbi.nlm.nih.gov/pubmed/32227284
http://dx.doi.org/10.1007/s40744-020-00201-y

Ejemplares similares